72 related articles for article (PubMed ID: 24788590)
1. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
[TBL] [Abstract][Full Text] [Related]
2. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
Lee KH; Chung JH; Cho S; Lee JS; Kim H
Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
[TBL] [Abstract][Full Text] [Related]
3. Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.
Onozato ML; Kovach AE; Yeap BY; Morales-Oyarvide V; Klepeis VE; Tammireddy S; Heist RS; Mark EJ; Dias-Santagata D; Iafrate AJ; Yagi Y; Mino-Kenudson M
Am J Surg Pathol; 2013 Feb; 37(2):287-94. PubMed ID: 23095504
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.
Isobe T; Hiyama K; Yoshida Y; Fujiwara Y; Yamakido M
Jpn J Cancer Res; 1994 Dec; 85(12):1240-6. PubMed ID: 7852188
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.
Kamigaichi A; Mimae T; Tsubokawa N; Miyata Y; Adachi H; Shimada Y; Ito H; Ikeda N; Okada M
Ann Thorac Surg; 2024 Apr; 117(4):743-751. PubMed ID: 36739066
[TBL] [Abstract][Full Text] [Related]
6. Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
Katsumata S; Shimokawa M; Hamada A; Haratake N; Nomura K; Fujino K; Yoshikawa M; Suzawa K; Shien K; Suda K; Ohara S; Fukuda S; Kinoshita F; Hayasaka K; Notsuda H; Takamori S; Muto S; Takanashi Y; Mizuno K; Kawase A; Hayakawa T; Sekihara K; Toda M; Matsuo S; Takegahara K; Hashimoto M; Nakahashi K; Endo M; Ozawa H; Fujikawa R; Tomioka Y; Namba K; Matsubara T; Suzuki J; Watanabe H; Takada K; Hoshino H; Kaiho T; Toyoda T; Kouki Y; Shiono S; Soh J; Ohde Y
Eur J Cancer; 2024 Apr; 201():113951. PubMed ID: 38417299
[TBL] [Abstract][Full Text] [Related]
7. Effect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study.
Aoki M; Miyata R; Kamimura G; Harada Takeda A; Suetsugu T; Mizuno K; Ueda K
Ann Thorac Cardiovasc Surg; 2024 Jan; 30(1):. PubMed ID: 38105006
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Leslie KK; Sill MW; Lankes HA; Fischer EG; Godwin AK; Gray H; Schilder RJ; Walker JL; Tewari K; Hanjani P; Abulafia O; Rose PG
Gynecol Oncol; 2012 Nov; 127(2):345-50. PubMed ID: 22885469
[TBL] [Abstract][Full Text] [Related]
9. Prognostic outcomes and recurrence patterns in resected stage I lung adenocarcinoma harbouring atypical epidermal growth factor receptor mutations.
Chen T; Wen J; Li Y; Deng J; Zhong Y; Hou L; She Y; Xie D; Chen C
Eur J Cardiothorac Surg; 2024 Jan; 65(1):. PubMed ID: 38001033
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia.
Ireland AP; Shibata DK; Chandrasoma P; Lord RV; Peters JH; DeMeester TR
Ann Surg; 2000 Feb; 231(2):179-87. PubMed ID: 10674608
[TBL] [Abstract][Full Text] [Related]
11. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
Kim Y; Ahn B; Yoon S; Lee G; Kim D; Chun SM; Kim HR; Jang SJ; Hwang HS
PLoS One; 2023; 18(6):e0287256. PubMed ID: 37347751
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes.
Matsubara D; Niki T; Ishikawa S; Goto A; Ohara E; Yokomizo T; Heizmann CW; Aburatani H; Moriyama S; Moriyama H; Nishimura Y; Funata N; Fukayama M
Cancer Sci; 2005 Dec; 96(12):844-57. PubMed ID: 16367903
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung.
Heist R; Azzoli CG
Oncologist; 2013; 18(12):1258-61. PubMed ID: 24277772
[TBL] [Abstract][Full Text] [Related]
14. Predictive advantage of a cell type classification for pulmonary adenocarcinoma coupled with data for p53, K-ras and EGFR alterations.
Okada A; Shimmyo T; Hashimoto T; Kobayashi Y; Miyagi Y; Ishikawa Y; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Sci; 2010 Jul; 101(7):1745-53. PubMed ID: 20491778
[TBL] [Abstract][Full Text] [Related]
15. Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance.
Goto A; Niki T; Chi-Pin L; Matsubara D; Murakami Y; Funata N; Fukayama M
Cancer Sci; 2005 Aug; 96(8):480-6. PubMed ID: 16108829
[TBL] [Abstract][Full Text] [Related]
16. Lectin histochemistry of resected adenocarcinoma of the lung: helix pomatia agglutinin binding is an independent prognostic factor.
Laack E; Nikbakht H; Peters A; Kugler C; Jasiewicz Y; Edler L; Hossfeld DK; Schumacher U
Am J Pathol; 2002 Mar; 160(3):1001-8. PubMed ID: 11891197
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of primary pulmonary adenocarcinoma after surgical resection in small-breed dogs: 52 cases (2005-2021).
Ichimata M; Kagawa Y; Namiki K; Toshima A; Nakano Y; Matsuyama F; Fukazawa E; Harada K; Katayama R; Kobayashi T
J Vet Intern Med; 2023; 37(4):1466-1474. PubMed ID: 37226683
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma.
Wilkinson NW; Black JD; Roukhadze E; Driscoll D; Smiley S; Hoshi H; Geradts J; Javle M; Brattain M
J Gastrointest Surg; 2004; 8(4):448-53. PubMed ID: 15120370
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary Low Malignant Potential Adenocarcinoma: A Validation of the Proposed Criteria for This Novel Subtype.
Pittaro A; Crivelli F; Orlando G; Napoli F; Zambelli V; Guerrera F; Sobrero S; Volante M; Righi L; Papotti M
Am J Surg Pathol; 2024 Feb; 48(2):204-211. PubMed ID: 37981865
[TBL] [Abstract][Full Text] [Related]
20. Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
Chang JG; Chen CC; Wu YY; Che TF; Huang YS; Yeh KT; Shieh GS; Yang PC
Oncotarget; 2016 Nov; 7(45):73664-73680. PubMed ID: 27655641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
